CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis

ObjectiveChimeric antigen receptor T-cell immunotherapy (CAR-T) is a preferred treatment for relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Several trials have evaluated CD20×CD3 bispecific antibodies (BsAbs) as subsequent therapy in R/R LBCL. This study aimed to investigate the efficacy...

Descripción completa

Detalles Bibliográficos

Autores principales:	Jing Shen, Jingyi Zhang, Zhengyu Zhu, Haobo Ma, Xiayan Li, Junpeng Zhang, Fan Zhou, Hua Tian, Jinghua Liu
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2025-08-01
Colección:	Frontiers in Oncology
Materias:	bispecific antibody meta-analysis CAR-T cell therapy relapsed or refractory large B-cell lymphoma
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1641769/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!